Ziad A Ali, MD
Psychiatry · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 12 years
- Graduated 2014
Offices
1 location · Mark David Levine MD Professional Corporation · 165 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Ali’s office at (855) 501-1004 to ask if they take your plan before you enroll.
Medicaid work
$9,425 in 2024
Medicaid paid $9,425 for 30 billed services this clinician did in 2024, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 17 | $5,018 |
| Psychiatric diagnostic evaluation with medical services | 13 | $4,407 |
| 2024 | 30 | 2 | 13 | $9,425 |
Drugs they prescribed that Part D paid
$38,573
Pharmacies billed $38,573 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 317) in 2024. At or below the middle of the specialty; the typical psychiatry clinician is at 0%.
302 generic and 15 brand-name prescriptions · $38,573 in drug cost · 14 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Venlafaxine Hcl Er | 26 | $862 | $33 |
| Mirtazapine | 16 | $504 | $31 |
| Trazodone | 20 | $443 | $22 |
| Buspirone | 17 | $322 | $19 |
| Fluoxetine | 24 | $268 | $11 |
See all 11 drugs
| Venlafaxine Hcl Er | 26 | $862 | $33 |
| Mirtazapine | 16 | $504 | $31 |
| Trazodone | 20 | $443 | $22 |
| Buspirone | 17 | $322 | $19 |
| Fluoxetine | 24 | $268 | $11 |
| Duloxetine | 12 | $212 | $18 |
| Sertraline | 19 | $185 | $10 |
| Quetiapine | 14 | $167 | $12 |
| Hydroxyzine Pamoate | 11 | $146 | $13 |
| Aripiprazole | 12 | $125 | $10 |
| Lamotrigine | 11 | $81 | $7 |
Year by year
| 2024 | 317 | 62 | 0% (0) | 5% | $38,573 |
| 2023 | 1,020 | 91 | 0% (0) | 2% | $94,401 |
| 2022 | 205 | 35 | 0% (0) | None | $12,500 |
| 2021 | 52 | 13 | 0% (0) | None | $3,630 |
| 2020 | 15 | None | 0% (0) | None | $75 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Quetiapine Fumarate Er | 16 | $7,351 | $459 |
| Lurasidone | 18 | $6,274 | $349 |
| Divalproex Sodium Er | 20 | $4,762 | $238 |
| Quetiapine | 69 | $3,979 | $58 |
| Venlafaxine Hcl Er | 37 | $2,874 | $78 |
| Olanzapine | 16 | $2,105 | $132 |
| Trazodone | 87 | $1,651 | $19 |
| Buspirone | 46 | $1,126 | $24 |
| Doxepin | 41 | $1,056 | $26 |
| Desvenlafaxine Succinate Er | 25 | $1,012 | $40 |
| Duloxetine | 52 | $860 | $17 |
| Mirtazapine | 43 | $837 | $19 |
| Sertraline | 45 | $770 | $17 |
| Naltrexone | 14 | $724 | $52 |
| Aripiprazole | 20 | $718 | $36 |
| Divalproex | 25 | $560 | $22 |
| Hydroxyzine | 25 | $531 | $21 |
| Haloperidol | 18 | $529 | $29 |
| Bupropion Xl | 20 | $506 | $25 |
| Clonazepam | 35 | $502 | $14 |
| Lamotrigine | 50 | $497 | $10 |
| Hydroxyzine Pamoate | 29 | $492 | $17 |
| Propranolol | 23 | $456 | $20 |
| Methylphenidate | 12 | $397 | $33 |
| Oxcarbazepine | 17 | $376 | $22 |
| Lithium Carbonate Er | 14 | $284 | $20 |
| Diazepam | 26 | $196 | $8 |
| Fluoxetine | 26 | $156 | $6 |
| Lorazepam | 12 | $55 | $5 |
2022: 6 drugs
| Quetiapine | 21 | $2,794 | $133 |
| Duloxetine | 12 | $183 | $15 |
| Venlafaxine Hcl Er | 16 | $171 | $11 |
| Sertraline | 12 | $164 | $14 |
| Buspirone | 11 | $132 | $12 |
| Trazodone | 14 | $90 | $6 |
Money from drug and device companies
$219 in 2024
| 2024 | 6 | 10 | None | $219 |
| 2023 | 10 | 34 | None | $784 |
| 2022 | 6 | 24 | None | $468 |
| 2020 | 1 | 1 | None | $12 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Teva Pharmaceuticals USA | Austedo Xr | $66 | 3 payments
|
| Janssen Pharmaceuticals | Spravato | $45 | 2 payments
|
| Axsome Therapeutics | Auvelity | $36 | 2 payments
|
| Philips North America | (6574) Coronary Other | $35 | 1 payment
|
| Indivior | Perseris | $24 | 1 payment
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $14 | 1 payment
|
See all 10 published payments
| Teva Pharmaceuticals USA | Meals · 2024-12-16 | Austedo Xr | $18 |
| Philips North America | Meals · 2024-05-03 | (6574) Coronary Other | $35 |
| Janssen Pharmaceuticals | Meals · 2024-03-21 | Spravato | $23 |
| Axsome Therapeutics | Meals · 2024-03-20 | Auvelity | $16 |
| Indivior | Meals · 2024-03-12 | Perseris | $24 |
| Janssen Pharmaceuticals | Meals · 2024-02-14 | Spravato | $21 |
| Teva Pharmaceuticals USA | Meals · 2024-02-07 | Uzedy | $26 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2024-02-01 | Caplyta | $14 |
| Axsome Therapeutics | Meals · 2024-01-12 | Auvelity | $20 |
| Teva Pharmaceuticals USA | Meals · 2024-01-11 | Austedo Xr | $22 |
See earlier years (2023, 2022, 2020)
2023: $784
| Janssen Pharmaceuticals | Spravato | $375 | 12 payments
|
| Axsome Therapeutics | Auvelity | $85 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $80 | 4 payments
|
| Indivior | Perseris | $56 | 3 payments
|
| Otsuka America Pharmaceutical | Rexulti | $46 | 3 payments
|
| Alkermes | Lybalvi | $39 | 2 payments
|
| Idorsia Pharmaceuticals US | Quviviq | $37 | 2 payments
|
| Iti | Caplyta | $30 | 2 payments
|
| Ironshore Pharmaceuticals | Jornay Pm | $21 | 1 payment
|
| Teva Pharmaceuticals USA | Uzedy | $15 | 1 payment
|
2022: $468
| Iti | Caplyta | $195 | 11 payments
|
| Janssen Pharmaceuticals | Spravato | $84 | 4 payments
|
| Vanda Pharmaceuticals | Hetlioz | $84 | 4 payments
|
| Neurocrine Biosciences | Ingrezza | $40 | 2 payments
|
| Alkermes | Lybalvi | $38 | 2 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $27 | 1 payment
|
2020: $12
| Alexion Pharmaceuticals | Soliris | $12 | 1 payment
|
Professional record
- NPI
- 1750918041
- Licence
- KY R5425
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Psychiatry (2084P0800X)
- Mailing address
- 3835 N Freeway Blvd Ste 100, Sacramento, CA, 95834
- NPI first listed
- 2020-03-25
- NPI last updated
- 2024-07-05
- NPI record certified
- 2024-07-05
This is when the NPI record was last certified, not a medical board exam.